The Use of ARA290 for the Treatment of Diabetic Macular Oedema

NCT ID: NCT06626971

Last Updated: 2024-10-04

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-04-30
• Study Completion Date: 2017-08-31

Brief Summary

ARA 290-DMO is a prospective, open label, interventional, single centre, investigator led, phase II trial to examine the effect of ARA 290 on diabetic macular oedema in patients with type 1 or 2 diabetes.

The aim or primary objective of the study was to determine whether ARA 290 administered at a daily dose of 4mg subcutaneously for 12 weeks to patients with diabetes mellitus (DM) and DMO would have a beneficial effect on mean change in best corrected visual acuity (BCVA) from baseline values to week 12.

Detailed Description

Diabetic retinopathy a very most common cause of sight loss in people of working age. Sight loss occurs in diabetes because of diabetic macular oedema (DMO) and/or proliferative diabetic retinopathy (PDR), both are complications of diabetes in the eye.

In DMO fluid accumulates in the macula, the area responsible for our central sight. As the fluid accumulates the sight drops. The current treatments for DMO include laser and anti VEGF drugs and steroids. Anti VEGF drugs have been very helpful in the treatment of DMO. However, anti VEGF drugs need to be given by an injection into the eye, an Ophthalmologist (eye specialist) or a specialist nurse (a nurse trained for this purpose) will need to deliver this treatment to patients with DMO in the hospital.

Furthermore, patients require injections every four weeks during the first months of treatment and long term treatment is required. Moreover, not all patients respond to anti VEGFs: In 40% of patients the sight may not improve despite these injections. Because many patients with DMO have DMO in both eyes, injections need to be given in both eyes to many patients.

Given the above facts there appeared a clear need to develop new treatments for people with DMO. ARA 290 is a drug that has marked anti-inflammatory properties and has an effect in preventing the death of cells. As inflammation is known to play a role in the occurrence of DMO, it was thought that ARA 290 could potentially be helpful in treating patients with this condition. In light of this, the Investigators carried out this study to find out if ARA 290 was effective in drying the fluid in DMO. If this treatment was successful, benefits may have included a reduction of the demands on health care services and patient benefits of: self administration of the drug at home by the patients; a reduction in hospital visits; treatment of both eyes at once, reduced risks associated with injections; a more pleasant treatment (subcutaneous injection versus an injection into the eye).

Conditions

Diabetic Macular Oedema

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Intervention

Subcutaneous daily injection of ARA 290 at a dose of 4mg for 12 weeks.

Group Type: OTHER

ARA290

Intervention Type: DRUG

4 mg subcutaneous injections of ARA290 over an 84 day period

Interventions

ARA290

4 mg subcutaneous injections of ARA290 over an 84 day period

Intervention Type: DRUG

Other Intervention Names

L-Pyroglutamyl-L-glutamyl-L-glutaminyl-L-leucyl-L-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-L-serine

Eligibility Criteria

Inclusion Criteria

1. Patients with DR and centre involving DMO with a central subfield thickness of > 400 microns, as determined using SD-OCT;

2. >= 18 years of age

3. Clear media and naïve to previous treatments for DMO.

Exclusion Criteria

1. Macular oedema related to other retinal disease

2. Hazy media that prevents adequate retinal imaging

3. Allergy to fluorescein

4. Previous treatments for DMO

5. DMO with central subfield thickness of < 400 microns

6. Patients on systemic or topical steroids

7. Use of erythropoiesis stimulating agents within the two months prior to screening or during the trial

8. Treated with any other investigational medication or device within 60 days

9. Pregnant women, women who have not yet reached the menopause (no menses for 12 months or more without an alternative medical cause) who test positive for pregnancy or who are unwilling to take a pregnancy test prior to trial entry or are unwilling to undertake adequate precautions to prevent pregnancy for the duration of the trial.

10. Men who have a female partner and who are unwilling to undertake adequate precautions to prevent pregnancy for the duration of the trial.

11. Female patients who are breastfeeding

12. Active proliferative diabetic retinopathy (PDR) requiring treatment.

13. Patients with other eye diseases besides DR

14. Patients who are unable or unwilling to commit to the study schedule of events

15. Serious illness that is likely to affect the patient's ability to complete the study

Any patient showing a clinically significant improvement between the initial screening and presenting for the first screening/baseline visit may no longer be eligible for the study and will be recorded as a screen failure and will not be entered on to the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Araim Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: collaborator

Belfast Health and Social Care Trust

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Noemi Lois

Role: STUDY_CHAIR

Belfast Health & Social Care Trust and Queen's University Belfast

Locations

Belfast Health & Social Care Trust

Belfast, Co Antrim, United Kingdom

Countries

United Kingdom

Other Identifiers

14166NL-AS

Identifier Type: -

Identifier Source: org_study_id